NOTES-Assisted Laparoscopic Cholecystectomy Surgery

NCT ID: NCT00848146

Last Updated: 2012-07-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Refinements in laparoscopic surgery, coupled with advancements in therapeutic flexible endoscopy, have set the stage for surgery to move to even less invasive techniques to treat conditions in the GI tract and peritoneal cavity. Natural orifice translumenal endoscopic surgery (NOTES) offers a means of reducing and ultimately eliminating the need for abdominal incisions to gain access to the peritoneal cavity. In NOTES, a flexible endoscope and accessory instruments are inserted through a natural body orifice and passed through the wall of an organ to reach the abdominal cavity. By reducing or eliminating the need for abdominal incisions, NOTES may provide a least invasive surgical option that can reduce pain, recovery time, complications, and systemic inflammatory response when compared to a laparoscopic surgical approach. In this study, we propose to use the NOTES technique to eliminate the need for a 1.5-2.5 cm umbilical incision.

Hypothesis 1: We hypothesize that a combined endoscopic and laparoscopic approach will be able to eliminate a 1.5 to 2.5 cm infraumbilical incision when performing a laparoscopic cholecystectomy.

Hypothesis 2: Closure of the gastrotomy will be facilitated with the Ethicon TAS system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, we propose to use a surgical technique that eliminates the need for a 1.5-2.5 cm umbilical incision. All patients will receive pre-operative antibiotics. A Veress needle will be used to create pneumoperitoneum with insufflation of carbon dioxide gas by a standard laparoscopic insufflator. A 5 mm laparoscopic port will be inserted through the abdominal wall in the right mid-abdomen and a 5 mm laparoscope inserted for viewing the abdominal cavity. A flexible endoscope, positioned within a multi-lumen 18 mm therapeutic access device, will be inserted through the mouth and into the stomach. Using commercially available endoscopes, endoscopic instruments and accessories, a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. Additional laparoscopic trocars may be placed through the abdominal wall for laparoscopic instrument insertion to manipulate, retract and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. Intraoperative cholangiogram or laparoscopic ultrasound will be performed at the discretion of the surgeon. Once dissected free, the gallbladder will be removed through the stomach and out of the mouth with the aid of an endoscopic retrieval bag. Commercially available endoscopic clips, or FDA approved tissue anchors will be used to close the gastrotomy. Additionally, the gastrotomy closure will be tested for leaks and laparoscopically oversewn with suture.

Operative and recovery room times as well as hospital length of stay will be collected. During the hospital stay, severity of pain, use of pain medications and complications will be recorded. Patients will be discharged per the standard of practice for a laparoscopic cholecystectomy. All study patients will receive a call from a surgery clinic nurse on post-op day 2 and 7. We will develop a check list that will contain the following (yes/no) elements to be used prior to discharge, on the post-op day 2 and 7 phone calls, and the 2 week post-op clinic visit: pain controlled with meds, nausea, emesis, fever, chills, redness of incisions, drainage from incisions, shortness of breath, chest pain, yellow eyes, dark urine, clay-colored stools. If there are any "yes" responses to this checklist prior to discharge, the patient will not be discharged from the hospital. If there are any "yes" responses to this checklist at the post-op day 2 or 7 phone call, the patient will be advised to immediately come to the GI surgery clinic or go to the nearest emergency room. If there are any "yes" responses to this checklist at the 2 week clinic visit, the patient will undergo the necessary standard of care medical evaluation (labs, tests, etc.) and may be admitted to the hospital. These checklists will be reviewed by one of the investigators, collected and stored in a locked file cabinet.

Patients will return and be evaluated by their surgeon two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Additionally at this visit and at the preoperative visit, patients will complete a standardized Quality of Life (QOL) assessment (i.e., SF-36). Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record.

The potential advantages to the patients entered into this study include those mentioned above regarding elimination of post-operative wound infection and hernia but also the lack of abdominal incisions greater than 5 mm in length may reduce pain and recovery time and likely have a cosmetic advantage as well. Potential risks of this study involve the risks of the standard laparoscopic procedure including bleeding, infection, injury to surrounding structures and port/trocar site pain. Potential risks associated with use of flexible endoscopic instruments include esophageal perforation, bleeding and sore throat. In addition, there is the possibility that there may be new, unanticipated complications from this modified surgical technique. Patient risks will be mitigated by having the procedure performed by a surgeon with expertise in both laparoscopic surgery and flexible endoscopy, as well as having involvement of a skilled interventional gastroenterologist if deemed necessary.

This feasibility study will initially evaluate the potential benefit, risks and impact on the patient's quality of life of this modified surgical technique in 10 patients. Once a standardized technique is established and risks are shown to be low, a prospective comparative evaluation is planned to compare this modified technique to the standard laparoscopic approach.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholecystectomy, Laparoscopic Endoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NOTES-Assisted Lap Chole

These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).

Group Type EXPERIMENTAL

Endoscopically assisted Laparoscopic Cholecystectomy Surgery

Intervention Type PROCEDURE

Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopically assisted Laparoscopic Cholecystectomy Surgery

Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NOTES Natural orifice translumenal endoscopic surgery Transgastric Cholecystectomy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to undergo general anesthesia
* Age \> 18 yrs. of age and \< 85 yrs. of age
* Ability to give informed consent

Exclusion Criteria

* Acute cholecystitis
* BMI \> 40
* Contraindicated for esophagogastroduodenoscopy (EGD)
* Presence of common duct stones
* Presence of esophageal stricture
* Altered gastric anatomy
* Gallstone greater than 1.5cm diameter seen on pre-op ultrasound
* Pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ethicon Endo-Surgery

INDUSTRY

Sponsor Role collaborator

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eric Hungness

Assistant professor of surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric S Hungness, M.D.

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northwestern University

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NU IRB# 1452-006

Identifier Type: -

Identifier Source: secondary_id

23522

Identifier Type: -

Identifier Source: org_study_id